Enterprise Value
6.424B
Cash
1.527B
Avg Qtr Burn
-202.9M
Short % of Float
8.95%
Insider Ownership
34.88%
Institutional Own.
53.39%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTAMA (Tapinarof) Details Psoriasis | Approved Quarterly sales | |
Brepocitinib Details Diabetes mellitus , Systemic lupus erythematosus | Phase 3 Data readout | |
Phase 3 Data readout | ||
Namilumab Details Sarcoidosis | Phase 2 Data readout | |
RVT-3101 Details Ulcerative colitis | Phase 2 Data readout | |
RVT-2001 Details Myelodysplastic syndrome | Phase 1/2 Data readout |